International Stem Cell (ISCO) Net Income towards Common Stockholders (2010 - 2026)
International Stem Cell's Net Income towards Common Stockholders was -$71,000 in Q2 2026, compared with $67,000 a year earlier.
Powered by 
Analysis
International Stem Cell (ISCO) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, International Stem Cell's Net Income towards Common Stockholders was -$323,000 through Jun 30, 2026; for FY2025, it was -$418,000.
- In earlier years, Net Income towards Common Stockholders was -$209,000 in FY2024, -$131,000 in FY2023, -$331,000 in FY2022 and -$899,000 in FY2021.
- Quarterly Net Income towards Common Stockholders has moved between -$458,000 (Q4 2023) and $259,000 (Q2 2023) over five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | International Stem Cell | 2.40 Mn | -1.57 Mn | 1.46 Mn | -71,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Dec 31, 2025 | -348,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Mar 31, 2025 | -256,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | -125,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | -214,000.00 |
| Dec 31, 2023 | -458,000.00 |
| Sep 30, 2023 | -131,000.00 |
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | -34,000.00 |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | -343,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | -351,000.00 |
| Sep 30, 2021 | -165,000.00 |
| Jun 30, 2021 | 216,000.00 |
API Access
International Stem Cell Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ISCO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "ISCO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ISCO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();